OCA at 12:02, 1 February 2024

OCA — Thu, 01 Feb 2024 12:02:15 GMT

←Older revision		Revision as of 12:02, 1 February 2024
Line 1:		Line 1:

-	====	+	==FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH ZN(II), 3-methyl-2-oxoglutarate, AND TANKYRASE-2 (TNKS2) FRAGMENT PEPTIDE (21-MER)==
-	<StructureSection load='7a1s' size='340' side='right'caption='[[7a1s]]' scene=''>	+	<StructureSection load='7a1s' size='340' side='right'caption='[[7a1s]], [[Resolution\|resolution]] 2.01Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[7a1s]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7A1S OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7A1S FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7a1s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7a1s OCA], [https://pdbe.org/7a1s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7a1s RCSB], [https://www.ebi.ac.uk/pdbsum/7a1s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7a1s ProSAT]</span></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.01Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ROQ:(3~{S})-3-methyl-2-oxidanylidene-pentanedioic+acid'>ROQ</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7a1s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7a1s OCA], [https://pdbe.org/7a1s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7a1s RCSB], [https://www.ebi.ac.uk/pdbsum/7a1s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7a1s ProSAT]</span></td></tr>
	</table>		</table>
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/HIF1N_HUMAN HIF1N_HUMAN] Hydroxylates HIF-1 alpha at 'Asp-803' in the C-terminal transactivation domain (CAD). Functions as an oxygen sensor and, under normoxic conditions, the hydroxylation prevents interaction of HIF-1 with transcriptional coactivators including Cbp/p300-interacting transactivator. Involved in transcriptional repression through interaction with HIF1A, VHL and histone deacetylases. Hydroxylates specific Asn residues within ankyrin repeat domains (ARD) of NFKB1, NFKBIA, NOTCH1, ASB4, PPP1R12A and several other ARD-containing proteins. Also hydroxylates Asp and His residues within ARDs of ANK1 and TNKS2, respectively. Negatively regulates NOTCH1 activity, accelerating myogenic differentiation. Positively regulates ASB4 activity, promoting vascular differentiation.<ref>PMID:12080085</ref> <ref>PMID:12042299</ref> <ref>PMID:17003112</ref> <ref>PMID:18299578</ref> <ref>PMID:19245366</ref> <ref>PMID:17573339</ref> <ref>PMID:21251231</ref> <ref>PMID:21177872</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	2-Oxoglutarate (2OG) oxygenases are validated agrochemical and human drug targets. The potential for modulating their activity with 2OG derivatives has not been explored, possibly due to concerns regarding selectivity. We report proof-of-principle studies demonstrating selective enhancement or inhibition of 2OG oxygenase activity by 2-oxo acids. The human 2OG oxygenases studied, factor inhibiting hypoxia-inducible transcription factor HIF-alpha (FIH) and aspartate/asparagine-beta-hydroxylase (AspH), catalyze C3 hydroxylations of Asp/Asn-residues. Of 35 tested 2OG derivatives, 10 enhance and 17 inhibit FIH activity. Comparison with results for AspH reveals that 2OG derivatives selectively enhance or inhibit FIH or AspH. Comparison of FIH structures complexed with 2OG derivatives to those for AspH provides insight into the basis of the observed selectivity. 2-Oxo acid derivatives have potential as drugs, for use in biomimetic catalysis, and in functional studies. The results suggest that the in vivo activity of 2OG oxygenases may be regulated by natural 2-oxo acids other than 2OG.
		+
		+	2-Oxoglutarate derivatives can selectively enhance or inhibit the activity of human oxygenases.,Nakashima Y, Brewitz L, Tumber A, Salah E, Schofield CJ Nat Commun. 2021 Nov 10;12(1):6478. doi: 10.1038/s41467-021-26673-2. PMID:34759269<ref>PMID:34759269</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 7a1s" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Factor inhibiting HIF\|Factor inhibiting HIF]]
		+	*[[Hypoxia-Inducible factor 1 alpha inhibitor\|Hypoxia-Inducible factor 1 alpha inhibitor]]
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: ~~Z-disk~~]]	+	[[Category: Brewitz L]]
		+	[[Category: Nakashima Y]]
		+	[[Category: Schofield CJ]]

OCA at 06:16, 25 August 2021

OCA — Wed, 25 Aug 2021 06:16:31 GMT

←Older revision		Revision as of 06:16, 25 August 2021
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 7a1s ~~is ON HOLD until Paper Publication~~	+	====
-		+	<StructureSection load='7a1s' size='340' side='right'caption='[[7a1s]]' scene=''>
-	~~Authors~~:	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>
-	~~Description~~:	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7a1s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7a1s OCA], [https://pdbe.org/7a1s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7a1s RCSB], [https://www.ebi.ac.uk/pdbsum/7a1s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7a1s ProSAT]</span></td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	</table>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Large Structures]]
		+	[[Category: Z-disk]]

OCA at 07:32, 24 December 2020

OCA — Thu, 24 Dec 2020 07:32:41 GMT

←Older revision		Revision as of 07:32, 24 December 2020
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 7a1s is ON HOLD	+	The entry 7a1s is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "7a1s" [edit=sysop:move=sysop]

OCA — Wed, 19 Aug 2020 04:39:51 GMT

Protected "7a1s" [edit=sysop:move=sysop]

←Older revision

Revision as of 04:39, 19 August 2020

OCA: New page: '''Unreleased structure''' The entry 7a1s is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 19 Aug 2020 04:39:50 GMT

New page: '''Unreleased structure''' The entry 7a1s is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 7a1s is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]

7a1s - Revision history

OCA at 12:02, 1 February 2024

OCA at 06:16, 25 August 2021

OCA at 07:32, 24 December 2020

OCA: Protected "7a1s" [edit=sysop:move=sysop]

OCA: New page: '''Unreleased structure''' The entry 7a1s is ON HOLD Authors: Description: Category: Unreleased Structures